Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system
PLOS One · 27.10.2025 · 20 (10) · e0334513
DOI: 10.1371/journal.pone.0334513 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 27.10.2025. Verfasst von Mei Rao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Immunoconjugates, Adverse Drug Reaction Reporting Systems, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Longyan City Science and Technology Plan Project.
Abstract (Originalsprache)
Background
Although antibody-drug conjugates (ADCs) have shown significant efficacy in cancer treatment, hematotoxicity remains a serious issue. This study aims to investigate the relationship between ADCs and hematological toxicity.
Methods
Our study was conducted using data extracted from the U.S. Food and Drug Administration Adverse Events Reporting System (FAERS) from the third quarter of 2011 to the second quarter of 2024. We used four disproportionality analysis methods to measure risk signals. In addition, we analyzed the time-to-onset of hematotoxicity adverse events (AEs).
Results
A total of 4,803 cases of hematotoxicity AEs associated with ADCs were identified, the median age of patients was 60 years (IQR: 47–72). Different ADCs have different hematotoxicity profiles, among which brentuximab vedotin (BV) and sacituzumab govitecan (SG) were more likely to lead to serious outcomes. The median time-to-onset of hematotoxicity AEs was the shortest for SG at 12 days and the longest for trastuzumab deruxtecan (TG) at 22 days. The hospitalization and mortality rates with hematotoxicity AEs were 30.38% and 18.30%, respectively.
Conclusions
ADCs are significantly associated with increased reporting of hematotoxicity. A novel hematotoxicity signal that was not disclosed in the drug specifications was observed. The most prominent hematotoxicity AE signals were cytopenia related to inotuzumab ozogamicin (IO), polatuzumab vedotin (PV), loncastuximab tesirine (LT), and tisotumab vedotin (TV); febrile bone marrow aplasia related togemtuzumab ozogamicin (GO), BV, and SG; and myelosuppression related to BV, trastuzumab emtansine (TE), andenfortumab vedotin (EV). Our findings need to be validated by large-scale prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.
- The School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.
- Department of Obstetrical, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.
- Department of Radiology, The Second Hospital of Longyan City, Longyan, Fujian, China.
ORCID-Profile: Mei Rao, Chunmei Chen
Förderung
- Longyan City Science and Technology Plan Project
Zitieren
APA
Rao, M., Wu, L., Chen, H., Wu, X., Wang, H., Chen, Y., & Chen, C. (2025). Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system. PLOS One, 20(10), e0334513. https://doi.org/10.1371/journal.pone.0334513
Vancouver
Rao M, Wu L, Chen H, Wu X, Wang H, Chen Y, et al. Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system. PLOS One. 2025;20(10):e0334513. doi:10.1371/journal.pone.0334513
BibTeX
@article{Rao2025,
author = {Rao, Mei and Wu, Lihua and Chen, Hong and Wu, Xiaohui and Wang, Huiying and Chen, Yangyi and Chen, Chunmei},
title = {Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {10},
pages = {e0334513},
doi = {10.1371/journal.pone.0334513}
}
EUVIMED